At a glance
ClinicalIndex Comparison Record- ✓Type 2 diabetes diagnosis per Chinese guidelines with HbA1c 7–10%
- ✓Documented hyperglycemia: RBG≥11.1 mmol/L, or FPG≥7.0 mmol/L, or 2-hour post-load glucose≥11.1 mmol/L
- ✓Age 40–70 years
- ✓BMI 18–40 kg/m²
- ✕Incretin drugs within past 1 month
- ✕C-peptide <0.3 ng/mL
- ✕Allergy to GLP-1 or DPP4-i agents
- ✕Pregnancy or breast-feeding
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study on Polymorphism of DPP-4 and GLP-1R Genes in Chinese Population and Its Empirical Study on Treatment of Diabetes
In Brief
A Phase 4 clinical trial evaluating Sitagliptin for Diabetes Mellitus. Completed, enrolled 119 participants across 1 site.
Detailed Summary
Incretin-based therapy is currently one of the most popular diabetes treatment approaches. However, differences of response ware found in previous studies. We hypothesis that SNPs of DPP-4, GLP-1 and GLP-1R genes may play crucial roles in the response differences. Therefore, this study aims to investigate the correlation of incretin-related gene polymorphism and individual differences in the response of DPP-4 inhibators (take Sitagliptin as an example). In addition, The distribution differences of the SNPs in diabetics and non-diabetics are evaluated to study the relationships between the SNPs and diabetes onsets.
Study Details
Timeline
Interventions
100mg.QD for 3 months